{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu J"],"funding":["South University of Science and Technology of China"],"pagination":["e33937"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11269827"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(13)"],"pubmed_abstract":["Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy remain a subject of debate. In this research we investigated the efficiency and long-term outcomes of CD19 CAR-T bridging with allo-HSCT in R/R B-ALL patients. A total of 42 patients were brought into the cohort studies. Our findings revealed that patients who appected CAR-T followed by HSCT had a 1-year overall survival (OS) rate of 70 % and a 1-year leukemia-free survival (LFS) rate of 95 %. Moreover, patients who underwent this combined treatment had higher OS and LFS rates compared to t"],"journal":["Heliyon"],"pubmed_title":["CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia."],"pmcid":["PMC11269827"],"funding_grant_id":["2020-D6"],"pubmed_authors":["Liu J","Yu L","Xu M","Fu Y","Han X","Li L","Yu H","Zou X","Feng J","Zhang Z","Zhong T","Zhang X","Meng H","Kang L"],"additional_accession":[]},"is_claimable":false,"name":"CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia.","description":"Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy remain a subject of debate. In this research we investigated the efficiency and long-term outcomes of CD19 CAR-T bridging with allo-HSCT in R/R B-ALL patients. A total of 42 patients were brought into the cohort studies. Our findings revealed that patients who appected CAR-T followed by HSCT had a 1-year overall survival (OS) rate of 70 % and a 1-year leukemia-free survival (LFS) rate of 95 %. Moreover, patients who underwent this combined treatment had higher OS and LFS rates compared to t","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-02T23:34:49.725Z","creation":"2025-04-19T13:11:16.556Z"},"accession":"S-EPMC11269827","cross_references":{"pubmed":["39055833"],"doi":["10.1016/j.heliyon.2024.e33937"]}}